Iridex to Report Third Quarter 2024 Financial Results on November 12, 2024
Iridex to Report Third Quarter 2024 Financial Results on November 12, 2024
Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company's proprietary MicroPulse technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex's current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at .MOUNTAIN VIEW, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the third quarter 2024 and provide a business update after the close of trading on Tuesday, November 12, 2024.
加利福尼亞州芒廷維尤，2024年11月4日（環球社廣告）- 艾裏德克斯股份有限公司（NASDAQ：IRIX）是全球領先的提供創新和多功能激光醫療系統、輸送設備和用於青光眼和視網膜疾病治療的手術探針的公司。今天宣佈，公司將於2024年第三季度財務業績和業務更新在2024年11月12日星期二交易結束後發佈。
The Company's management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing 1-888-596-4144 for domestic callers or +1-646-968-2525 for international callers, using conference ID: 3650755. A live and recorded webcast on the "Event Calendar" page of the "Investors" section of the Company's website at .
公司管理團隊將於太平洋時間下午2:00 / 東部時間下午5:00開始召開對應的電話會議。有興趣收聽電話會議的投資者可以撥打1-888-596-4144（美國國內呼叫者）或+1-646-968-2525（國際呼叫者），會議ID號：3650755。公司網站「投資者」部分的「活動日曆」頁面上將提供現場和錄播網絡廣播。
About Iridex Corporation
關於艾裏德克斯公司
Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company's proprietary MicroPulse technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex's current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at .
艾裏德克斯股份有限公司是全球眼科醫療領域中發展、製造和營銷創新和多功能激光醫療系統、輸送設備和消耗品儀器的領先者。該公司擁有的MicroPulse技術提供了區別於衆的治療，爲針對威脅視力的眼部疾病提供安全、有效和經過驗證的治療。艾裏德克斯目前的產品線適用於青光眼和糖尿病性黃斑水腫（DME）等視網膜疾病的治療。艾裏德克斯的產品主要通過直銷隊伍在美國銷售，國際上主要通過獨立分銷商網絡銷往100多個國家。欲了解更多信息，請訪問艾裏德克斯網站。
MicroPulse is a registered trademark of Iridex Corporation, Inc. in the United States, Europe and other jurisdictions. 2024 Iridex Corporation. All rights reserved.
MicroPulse是艾裏德克斯公司在美國、歐洲和其他司法管轄區的註冊商標。2024年艾裏德克斯公司。保留所有權利。
Investor Relations Contact:
Philip Taylor
Gilmartin Group
investors@iridex.com
投資者關係聯繫人：
Philip Taylor
吉爾馬汀集團
investors@iridex.com
譯文內容由第三人軟體翻譯。
